Skip to main content
. 2011 Apr 7;118(4):874–883. doi: 10.1182/blood-2010-06-292615

Table 2.

Patient characteristics (randomized patients only)

T-cell leukemia
 NHL
 Total
No HDM HDM No HDM HDM
Age at diagnosis, y
    Younger than 10 85 78 31 38 232
    10 or older 66 70 35 33 204
Sex
    Male 109 111 52 55 327
    Female 42 37 14 16 109
Race
    White 113 116 51 56 336
    Black 32 23 11 10 76
    Other 6 9 4 4 23
    Unknown 0 0 0 1 1
CNS status
    No data 1 1 4 0 6
    CNS 1 102 109 60 69 340
    CNS 2 34 24 0 0 58
    CNS 3 9 12 2 2 25
    Bloody tap, blasts 3 2 0 0 5
    Bloody tap, cannot interpret 1 0 0 0 1
    Cranial nerve involvement only 1 0 0 0 1
WBC, × 1000/μL
    < 50 61 64 66 71 262
    50+ 90 84 0 0 174
Lymphadenopathy
    Missing 0 0 3 2 5
    No 27 38 26 21 112
    Yes 124 110 37 48 319
Mediastinal mass
    No 59 63 11 13 146
    Yes 92 85 55 58 290
Bulky disease (lymphadenopathy and mediastinal mass)
    Missing 0 0 3 2 5
    No 73 86 34 33 226
    Yes 78 62 29 36 205
Splenomegaly (spleen palpable below umbilicus)
    Missing 0 0 2 3 5
    No 106 100 57 64 121
    Yes 45 48 8 6 14
Stage (T-NHL only)
    Missing 0 1 1
    III 44 46 90
    IV 23 26 49

NHL indicates non-Hodgkin lymphoma; and HDM, high-dose methotrexate.

HHS Vulnerability Disclosure